Bispecific antibody vesicles: A multifunctional bioactive drug delivery platform for the treatment of Pseudomonas aeruginosa infection

ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES · Published 2026-05-17 · DOI 10.1016/j.ajps.2026.101162

Free full text

Authors (11)

Jiaxin Ma, Zihao Teng, Xuqi Peng, Yanyin Wang, Linyu Ding, Yijia Xie, Wenhui Huang, Qiuyue Long, Jianzhong Zhang, Lai Jiang, Gang Liu

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is a major pulmonary pathogen that establishes chronic infection through Psl polysaccharide-mediated adhesion and biofilm formation, while accelerating acute disease via toxin injection through the type III secretion system (T3SS) PcrV protein. Conventional small-molecule antibiotics show poor target specificity, limited biofilm penetration and insufficient toxin neutralization, thereby compromising therapeutic efficacy. Here, we developed a bioactive nano delivery system that integrates a bispecific antibody (BsAb) with a nano-antibiotic for P. aeruginosa infection. Specifically, an anti-Psl single-chain variable fragment (scFv) was linked with an anti-PcrV monoclonal antibody (mAb) to generate the BsAb, which was subsequently displayed on cellular outer membranes and harvested as nanoscale membrane vesicles displaying BsAb (BsAb-MVs). Gentamicin (Gen)-loaded poly (lactic-co-glycolic acid) nanoparticles (GNPs) were coated with BsAb-MVs to form BsAb-functionalized GNPs (BsAb-GNPs). By leveraging high-affinity recognition of bacterial surface antigens and enhanced antibiotic penetration, BsAb-GNPs showed robust bactericidal activity by precisely targeting planktonic bacteria and biofilms, imposing effective local drug concentration. Moreover, BsAb-MVs retained antibody-mediated adhesion neutralization and host-cell invasion blockade, thereby mitigating toxin-induced tissue damage. In vitro biofilm assays and a murine pneumonia model confirmed the precise targeting and potent antibacterial efficacy of BsAb-GNPs. Collectively, this antibody-antibiotic system integrated multifunctional antibody-antibiotic therapeutic strategy for biofilm-associated infections and offers immunological advantages, which may provide a scalable and translational strategy against P. aeruginosa biofilm infections.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Citation

Ma, J., Teng, Z., Peng, X., et al. (2026). Bispecific antibody vesicles: A multifunctional bioactive drug delivery platform for the treatment of Pseudomonas aeruginosa infection. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES. https://doi.org/10.1016/j.ajps.2026.101162

Related articles